)
Visual24 Oct 2025
The rise of Alphabet
Ensysce Biosciences (ENSC) investor relations material
Ensysce Biosciences Q2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2025 earnings summary13 Aug, 2025
Executive summary
Lead product candidate PF614 is in Phase 3, with PF614-MPAR in Phase 1b and nafamostat completed Phase 1; no products approved or commercialized yet.
Initiated pivotal Phase 3 trial for PF614, aiming to validate superior pain relief with built-in abuse deterrence and overdose protection.
Fully enrolled Part 2 of PF614-MPAR-102 study, advancing overdose-protection opioid candidate.
Received $5.3 million NIDA grant installment to support overdose protection program.
Operating losses continue, with expectations for increased expenses as clinical programs advance and infrastructure expands.
Financial highlights
Cash and cash equivalents were $2.2 million as of June 30, 2025, down from $3.5 million at year-end 2024.
Net loss for Q2 2025 was $1.7 million, compared to $2.0 million in Q2 2024; net loss for the first half of 2025 was $3.7 million, down from $5.1 million in the prior year period.
Federal grant revenue was $1.4 million in Q2 2025, up from $0.2 million in Q2 2024, reflecting increased research activity.
Research and development expenses rose to $1.9 million in Q2 2025 from $0.9 million in Q2 2024, driven by clinical and preclinical activity.
Net cash used in operating activities was $4.4 million for the first half of 2025, with $3.1 million provided by financing activities.
Outlook and guidance
Expenses and capital requirements are expected to increase as clinical trials progress and infrastructure expands.
Without additional capital, current cash is sufficient to fund operations into the fourth quarter of 2025.
Advancing clinical and regulatory milestones for PF614, PF614-MPAR, and OUD programs in the second half of 2025.
When will PF614-MPAR-102 study's Part 3 be completed?
Assess PF614's potential impact on opioid treatment.
Explain the increase in R&D expenses in Q2 2025.
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Ensysce Biosciences earnings date
Q3 202511 Nov, 2025
Next Ensysce Biosciences earnings date
Q3 202511 Nov, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Ensysce Biosciences Inc. is a clinical-stage pharmaceutical company focused on developing innovative drug delivery technologies aimed at improving safety in pain management. The company is known for its development of two proprietary platforms: the Trypsin Activated Abuse Protection (TAAP) and Multi-Pill Abuse Resistance (MPAR). These platforms are designed to reduce the risks associated with prescription opioid misuse, abuse, and overdose by enhancing the safety of oral drug delivery. Ensysce's product pipeline includes prodrug technologies that aim to provide effective pain relief while mitigating the potential for abuse and overdose. The company is headquartered in La Jolla, California, and its shares are listed on the NASDAQ under the ticker symbol ENSC.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage